Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CTSV | O60911 | 3/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 3/20 | 0.51 |
| ▸ | CTSS | P25774 | 3/20 | 0.51 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.48 |
| ▸ | PYGL | P06737 | 2/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923367 | 1.00 | GPR139 (0.54) | GPR139MEN1KMT2AATMCTSV | |
| SCHEMBL23923394 | 0.91 | GPR139 (0.51) | GPR139KMT2ACTSLCTSSCTSK | |
| SCHEMBL23923396 | 0.91 | GPR139 (0.51) | GPR139KMT2ACTSLCTSSCTSK | |
| SCHEMBL23923355 | 0.91 | SLC6A9 (0.54) | GPR139MEN1KMT2AATMCTSV | |
| SCHEMBL23923352 | 0.91 | SLC6A9 (0.54) | GPR139MEN1KMT2AATMCTSV | |
| SCHEMBL23923530 | 0.88 | GPR139 (0.54) | GPR139KMT2ASLC6A9SLC6A5PYGL | |
| SCHEMBL23923553 | 0.88 | GLA (0.51) | GPR139CTSLCTSBCTSSCTSK | |
| SCHEMBL23923554 | 0.88 | GLA (0.51) | GPR139CTSLCTSBCTSSCTSK | |
| SCHEMBL23923528 | 0.88 | GPR139 (0.54) | GPR139KMT2ASLC6A9SLC6A5PYGL | |
| SCHEMBL23923343 | 0.85 | KMT2A (0.47) | GPR139KMT2AATMCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11850247-B2 | Antiviral compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2023-12-26 | — | — | US | disclosed |
| US-20210322416-A1 | ANTIVIRAL COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-10-21 | — | — | US | disclosed |
| US-20210322416-A1 | ANTIVIRAL COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850247-B2 | Antiviral compounds | ZC3HAV1, ZC3HAV1L, CD4 | GPR139 2504/4885MEN1 2045/4885KMT2A 3667/4885 |
| US-20210322416-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, ZC3HAV1L, CD4 | GPR139 2504/4885MEN1 2045/4885KMT2A 3667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.